We are live on
!
Find out more
RSS
Rosenblum Silverman Sutton Portfolio holdings
AUM
$382M
1-Year Est. Return
13.82%
This Fund
S&P 500
This Quarter
Est. Return
+14.37%
1 Year Est. Return
+13.82%
3 Year Est. Return
+95.36%
5 Year Est. Return
+122.03%
10 Year Est. Return
+858.24%
AUM
$236M
AUM Growth
+$24.9M
(+12%)
Cap. Flow
-$311K
Cap. Flow
% of AUM
-0.13%
Top 10 Holdings %
Top 10 Hldgs %
39.67%
Holding
68
New
5
Increased
16
Reduced
36
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$3.15M |
| 2 |
Celanese
CE
|
+$2.96M |
| 3 |
Citizens Financial Group
CFG
|
+$2.34M |
| 4 |
Atkore
ATKR
|
+$1.97M |
| 5 |
ON Semiconductor
ON
|
+$1.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
American International
AIG
|
+$4.26M |
| 2 |
Gilead Sciences
GILD
|
+$3.28M |
| 3 |
NVIDIA
NVDA
|
+$1.36M |
| 4 |
WOOF
VCA Inc.
WOOF
|
+$1.1M |
| 5 |
American Tower
AMT
|
+$568K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.54% |
| 2 | Consumer Discretionary | 14.93% |
| 3 | Healthcare | 14.2% |
| 4 | Communication Services | 13.49% |
| 5 | Financials | 12.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Aclaris Therapeutics
ACRS
$793M
| $977K | 0.41% |
32,750
+11,600
| +55% | +$334K |
|
52
Morgan Stanley
MS
$339B
| $973K | 0.41% |
22,707
-950
| -4% | -$42.2K |
|
53
RTX Corp
RTX
$261B
| $829K | 0.35% |
11,735
+5,220
| +80% | +$366K |
|
54
Brunswick
BC
$5.23B
| $693K | 0.29% |
11,330
+3,120
| +38% | +$184K |
|
|
55
Gilead Sciences
GILD
$167B
| $675K | 0.29% |
9,945
-46,641
| -82% | -$3.28M |
|
56
DexCom
DXCM
$29.6B
| $668K | 0.28% |
31,524
-3,000
| -9% | -$58.6K |
|
57
S&P Global
SPGI
$133B
| $586K | 0.25% |
4,479
| – | – |
|
58
Comfort Systems
FIX
$58.9B
| $425K | 0.18% |
11,600
| – | – |
|
|
EGRX
59
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $354K | 0.15% |
4,265
-25
| -0.6% | -$1.86K |
|
60
Berkshire Hathaway Class B
BRK.B
$1.06T
| $297K | 0.13% |
+1,780
| New | +$298K |
|
61
3M
MMM
$83.4B
| $271K | 0.11% |
1,692
-120
| -7% | -$18.4K |
|
|
GTT
62
DELISTED
GTT Communications, Inc.
GTT
| $258K | 0.11% |
10,600
| – | – |
|
|
63
American International
AIG
$42.7B
| – | – |
-65,302
| Closed | -$4.26M |
|
64
Bristol-Myers Squibb
BMY
$124B
| – | – |
-8,885
| Closed | -$519K |
|
|
LDL
65
DELISTED
Lydall, Inc.
LDL
| – | – |
-5,000
| Closed | -$309K |
|
|
JCP
66
DELISTED
J.C. Penney Company, Inc.
JCP
| – | – |
-53,750
| Closed | -$447K |
|
|
TSRO
67
DELISTED
TESARO, Inc.
TSRO
| – | – |
-2,080
| Closed | -$280K |
|
Similar funds
STP
LWM
DSA
RC
NFP
MADR
MVP
BFP
Rosenblum Silverman Sutton's Q1 2017 Portfolio in Review
As of Q1 2017, Rosenblum Silverman Sutton held 68 positions worth $236M, up 12% from $211M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Rosenblum Silverman Sutton's Q1 2017 filing shows 5 new, 16 increased, 36 reduced and 5 closed positions. Its largest new stake was Portola Pharmaceuticals, Inc.: 98,785 shares worth $3.87M. The largest sale was American International, an estimated $4.26M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Rosenblum Silverman Sutton's largest Q1 2017 buy was Portola Pharmaceuticals, Inc.: 98,785 shares worth $3.87M.
- Rosenblum Silverman Sutton added most to Celanese in Q1 2017, an estimated $2.96M increase.
- Rosenblum Silverman Sutton's biggest Q1 2017 reduction was Gilead Sciences, cutting an estimated $3.28M.
- Rosenblum Silverman Sutton fully exited American International in Q1 2017, selling an estimated $4.26M.
- Rosenblum Silverman Sutton's ten largest holdings make up 40% of its $236M portfolio in Q1 2017.
- Rosenblum Silverman Sutton opened 5 new positions and closed 5 in Q1 2017.
- Rosenblum Silverman Sutton's portfolio value rose 12% quarter-over-quarter to $236M.
Based on Rosenblum Silverman Sutton's 13F filing for Q1 2017, filed 12 May 2017.